82121-06-0

Basic information

• Product Name: 7-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID
• Synonyms: 7-BROMO-4-HYDROXYQUINOLINE;7-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID;BUTTPARK 100\01-52;BUTTPARK 89\01-98;7-Bromo-4-quinolinol;8-aminoquinolin-4-ol;4-Quinolinol, 7-bromo-
• CAS NO: 82121-06-0
• Molecular Formula: C₉H₆BrNO
• Molecular Weight: 224.06
• EINECS: -0
• Mol File: 82121-06-0.mol

Chemical Properties

• Melting Point: 279-281 °C
• Boiling Point: 370.732oC at 760 mmHg
• Flash Point: 178.013oC
• Appearance: /
• Density: 1.705g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.718
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 3.83±0.40(Predicted)
• CAS DataBase Reference: 7-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID(82121-06-0)
• EPA Substance Registry System: 7-BROMO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID(82121-06-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 82121-06-0(Hazardous Substances Data)

Usage

Chemical Properties

Class color solid

InChI:InChI=1/C9H6BrNO/c10-6-1-2-7-8(5-6)11-4-3-9(7)12/h1-5H,(H,11,12)

Upstream product

• 860205-92-1 7-bromo-4-hydroxy-3-quinolinecarboxylic acid 
• 134785-82-3 7-bromo-4-hydroxy-quinoline-2-carboxylic acid 
• 723280-91-9 5-(((3-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 591-19-5 m-Bromoaniline 
• 351893-47-5 ethyl α-carbethoxy-β-m-bromoanilinoacrylate 
• 208580-23-8 7-bromo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 99-90-1 para-bromoacetophenone 
• 73387-60-7 (2E)-1-(4-bromophenyl)-3-(dimethylamino)prop-2-en-1-one 
• 153952-03-5 7-bromo-4-hydroxy-quinoline-2-carboxylic acid ethyl ester 
• 208580-23-8 ethyl 7-bromo-4-hydroxyquinoline-3-carboxylate 
• 2033-24-1 cycl-isopropylidene malonate 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 723280-94-2 7-bromo-3-nitroquinolin-4-ol 
• 1445786-68-4 3-((3-carbamoyl-7-(2,4-dimethoxypyrimidin-5-yl)-3-sulfamoylquinolin-4-yl)amino)-5-(cyclohexylmethoxy)benzoic acid 
• 1445789-28-5 methyl 3-((3-carbamoyl-7-(2,4-dimethoxypyrimidin-5-yl)-3-sulfamoylquinolin-4-yl)amino)-5-(cyclohexylmethoxy)benzoate 
• 1445786-87-7 7-(2,4-dimethoxypyrimidin-5-yl)-4-((3-(hydroxymethyl)phenyl)amino)quinoline-3-sulfonamide 
• 1445787-13-2 4-((3-cyclopentyl-5-(hydroxymethyl)phenyl)amino)-7-(2,4-dimethoxypyrimidin-5-yl)quinoline-3-sulfonamide 
• 1445787-25-6 4-((3-(1H-tetrazol-5-yl)phenyl)amino)-7-(2,4-dimethoxypyrimidin-5-yl)quinoline-3-sulfonamide 
• 1445787-44-9 3-((7-(2,4-dimethylpyrimidin-5-yl)-3-sulfamoylquinolin-4-yl)amino)-5-isopropoxybenzoic acid 
• 1445790-89-5 methyl 3-((7-bromo-3-sulfamoylquinolin-4-yl)amino)-5-isopropoxybenzoate 
• 1445790-91-9 methyl 3-((7-(2,4-dimethylpyrimidin-5-yl)-3-sulfamoylquinolin-4-yl)amino)-5-isopropoxybenzoate 
• 1445788-38-4 7-(2,4-dimethoxypyrimidin-5-yl)-4-((3-((4-fluorophenyl)amino)-5-(2H-tetrazol-5-yl)phenyl)amino)quinoline-3-sulfonamide 
• 1445786-52-6 3-(cyclohexyloxy)-5-((7-(2,4-dimethoxypyrimidin-5-yl)-3-sulfamoylquinolin-4-yl)amino)benzoic acid 
• 1445788-90-8 methyl 3-(cyclohexyloxy)-5-((7-(2,4-dimethoxypyrimidin-5-yl)-3-sulfamoylquinolin-4-yl)amino)benzoate 
• 1445786-56-0 3-(cyclopentyloxy)-5-((7-(2,4-dimethoxypyrimidin-5-yl)-3-sulfamoylquinolin-4-yl)amino)benzoic acid 
• 1445786-58-2 4-((3-(cyclohexyloxy)phenyl)amino)-7-(2,4-dimethoxypyrimidin-5-yl)quinoline-3-sulfonamide 

Relevant articles and documents

PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS

Disclosed herein are compounds of Formula (I) which inhibit, regulate and/or modulate tyrosine kinase receptors, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities, compositions containing the compounds, methods of using the compounds to treat kinase-dependent diseases and conditions, and methods for making the compounds.

Design, synthesis and biological evaluation of new quinoline derivatives as potential antitumor agents

A series of new quinoline derivatives was designed, synthesized and evaluated for their antiproliferative activity. The results demonstrated that compounds 11p, 11s, 11v, 11x and 11y exhibited potent antiproliferative activity with IC50 value of lower than 10 μM against seven human tumor cell lines, and N-(3-methoxyphenyl)-7- (3-phenylpropoxy)quinolin-4-amine 11x was found to be the most potent antiproliferative agent against HCT-116, RKO, A2780 and Hela cell lines with an IC50 value of 2.56, 3.67, 3.46 and 2.71 μM, respectively. The antitumor efficacy of the representative compound 11x in mice was also evaluated, and the results showed that compound 11x effectively inhibited tumor growth and decreased tumor weight in animal models. Further investigation on mechanism of action indicated that compound 11x could inhibit colorectal cancer growth through ATG5-depenent autophagy pathway. Therefore, these quinoline derivatives are a new class of molecules that have the potential to be developed as new antitumor drugs.

APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS

Described herein are ASK1 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with ASK1 activity.

For antibacterial chlorine oxygen kui derivatives

The invention relates to an oxo-quinoline derivative with activity of resisting bacterial infection relevant diseases such as helicobacter pylori (Hp) infection disease. The invention specifically relates to a compound as shown in formula I in the specification, and a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R is selected from hydrogen, -C alkyl, -C alkenyl, -C alkynyl, or -C alkyl-phenyl, and the alkyl, alkenyl, alkynyl and phenyl can be randomly substituted by halogen, nitro, cyan, hydroxyl, -C alkoxy and phenyl; R is selected from hydrogen, -CONHR and -COOR, R and R are independently selected from -C alkyl and -C alkyl amino, and the amino is randomly substituted by one to two -C alkyls; R is selected from halogen, -C alkoxy, morpholinyl or piperazinyl.

With anti-tumor activity of chlorine oxygen kui derivatives

The invention relates to a chloroxoquinoline derivatives with anti-tumor activity and specifically relates to compounds of a formula I as shown in the specification and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein R1 is selected from hydrogen, -C1-6 alkyl, -C2-6 alkenyl, -C2-6 alkynyl and -C1-6 alkyl-phenyl, and the alkyl, the alkenyl, the alkynyl and the phenyl can be optionally substituted by halogens, nitryl, cyan, hydroxyl, -C1-6 alkoxy and phenyl; R3 is selected from hydrogen, -CONHR31 and -COOR32, the R31 and the R32 are independently selected from -C1-6 alkyl and -C1-6 alkylamino, respectively, and the amino can be optionally substituted by 1 to 2 -C1-6 alkyls; R7 is selected from halogens, -C1-6 alkoxy, morpholinyl and piperazine; the formula I is as shown in the specification.

Co(III)-Catalyzed Enaminone-Directed C-H Amidation for Quinolone Synthesis

We report herein the development of a Co(III)-catalyzed enaminone-directed C-H amidation method for synthetic access to quinolones, an important heterocyclic scaffold for diverse pharmaceutically active structures. The C-H coupling with dioxazolones and subsequent deacylation of an installed amide group allow consecutive C-N coupling generation of quinolones with wide-ranging compatible substituent patterns.

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.

Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity

We previously reported that substituted 4-aminoquinolines with a phenyl ether substituent at the 7-position of the quinoline ring and the capability of intramolecular hydrogen bonding between the protonated amine on the side chain and a hydrogen bond acceptor on the amine's alkyl substituents exhibited potent antimalarial activity against the multidrug resistant strain P. falciparum W2. We employed a parallel synthetic method to generate diaryl ether, biaryl, and alkylaryl 4-aminoquinoline analogues in the background of a limited number of side chain variations that had previously afforded potent 4-aminoquinolines. All subsets were evaluated for their antimalarial activity against the chloroquine-sensitive strain 3D7 and the chloroquine-resistant K1 strain as well as for cytotoxicity against mammalian cell lines. While all three arrays showed good antimalarial activity, only the biaryl-containing subset showed consistently good potency against the drug-resistant K1 strain and good selectivity with regard to mammalian cytotoxicity. Overall, our data indicate that the biaryl-containing series contains promising candidates for further study.

Synthesis of novel halogenated 4(1H)-quinolones by thermolysis of arylaminomethylene-1,3-dioxane-4,6-diones

A variety of novel 4(1H)-quinolone derivatives were prepared by thermolysis of aminomethylene Meldrum's acid derivatives. Georg Thieme Verlag Stuttgart.